Can a Long-Acting antifungal reach the Belly's hidden infection?

NCT ID NCT06985758

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are studying rezafungin, an antifungal given by IV, in adults with suspected or confirmed Candida peritonitis, a fungal infection inside the abdomen. The trial measures how much drug gets into peritoneal fluid compared with blood levels. Twenty participants receive a first dose of 400 mg followed by weekly 200 mg doses. The goal is to see whether rezafungin reaches the infection site well enough to help treat it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rezafungin, an antifungal drug given intravenously
What this could lead to
If rezafungin reaches high enough levels in peritoneal fluid, it could offer a more reliable way to treat Candida infections inside the abdomen.
What could go wrong
This is a small, single-arm study of 20 people, so it cannot prove the drug works better than other treatments. It only measures drug levels, not whether patients recover faster.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with suspicion, confirmed or not, of candidiasis peritonitis or intra-abdominal infection by Candida spp. who, after having received information about the design, the purpose of the study, the possible risks that may arise from it and that they can refuse to collaborate at any time, give written consent to participate in the study. * Be over 18 years of age * Understand the purpose of the study and be available to perform the visits and procedures established in the protocol * In women: negative urine pregnancy test performed in the 7 days prior to the start of study treatment in women of childbearing age and if \< 2 years have passed after menopause * Patients with signs of peritonitis or intra-abdominal infection showing refractoriness after at least 48 hours of empirical or specific antibiotherapy and in whom candidiasis infection is suspected. * Patients with abdominal or peritoneal drainage with permeable debit that allows obtaining peritoneal samples through it. Exclusion Criteria: * Patients in whom there is any contraindication for use according to the established in the technical data sheet or known hypersensitivity to rezafungin or who, according to the investigator's criteria, it is not advisable to participate. * Patients who do not present suspicion of intra-abdominal candidiasis infection or who are receiving antifungal treatment for another reason. * Patients receiving another antifungal drug during rezafungin administration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Candidal peritonitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Clínico Universitario de Valencia

    Valencia, Valencia, 46010, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, 28046, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, 28034, Spain